Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naïve individuals: A systematic review of detection methods, prevalence, and clinical impact.

Mbunkah HA, Bertagnolio S, Hamers RL, Hunt G, Inzaule S, Rinke de Wit TF, Paredes R, Parkin NT, Jordan MR, Metzner KJ; WHO HIVResNet working group.

J Infect Dis. 2019 Dec 6. pii: jiz650. doi: 10.1093/infdis/jiz650. [Epub ahead of print]

PMID:
31809534
2.

Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.

Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Kok YL, Thorball CW, Borghesi A, Parbhoo S, Wieser M, Böni J, Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M, Kouyos RD, Günthard HF, Metzner KJ; Swiss HIV Cohort Study.

Nat Commun. 2019 Jul 19;10(1):3193. doi: 10.1038/s41467-019-10884-9.

3.

Parallel evolution of HIV-1 in a long-term experiment.

Bertels F, Leemann C, Metzner KJ, Regoes R.

Mol Biol Evol. 2019 Jun 28. pii: msz155. doi: 10.1093/molbev/msz155. [Epub ahead of print]

4.

Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.

Carlisle LA, Turk T, Kusejko K, Metzner KJ, Leemann C, Schenkel CD, Bachmann N, Posada S, Beerenwinkel N, Böni J, Yerly S, Klimkait T, Perreau M, Braun DL, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

J Infect Dis. 2019 Jun 19;220(2):254-265. doi: 10.1093/infdis/jiz094.

PMID:
30835266
5.

Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era.

Salazar-Vizcaya L, Kouyos RD, Metzner KJ, Caraballo Cortes K, Böni J, Shah C, Fehr J, Braun DL, Bernasconi E, Mbunkah HA, Hoffmann M, Labhardt N, Cavassini M, Rougemont M, Günthard HF, Keiser O, Rauch A; Swiss HIV Cohort Study.

J Infect Dis. 2019 Jun 5;220(1):91-99. doi: 10.1093/infdis/jiz069.

6.

Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.

Braun DL, Turk T, Tschumi F, Grube C, Hampel B, Depmeier C, Schreiber PW, Brugger SD, Greiner M, Steffens D, De Torrenté-Bayard C, Courlet P, Neumann K, Kuster H, Flepp M, Bertisch B, Decosterd L, Böni J, Metzner KJ, Kouyos RD, Günthard HF.

Clin Infect Dis. 2019 Oct 15;69(9):1489-1497. doi: 10.1093/cid/ciy1131.

PMID:
30601950
7.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study.

Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10.

PMID:
30202088
8.

Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector.

Kok YL, Schmutz S, Inderbitzin A, Neumann K, Kelley A, Jörimann L, Shilaih M, Vongrad V, Kouyos RD, Günthard HF, Berens C, Metzner KJ.

Sci Rep. 2018 Jul 5;8(1):10204. doi: 10.1038/s41598-018-28161-y.

9.

Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study.

Sculier D, Doco-Lecompte T, Yerly S, Metzner KJ, Decosterd LA, Calmy A.

HIV Med. 2018 Jun 22. doi: 10.1111/hiv.12626. [Epub ahead of print]

10.

Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16.

Mbunkah HA, Marzel A, Schmutz S, Kok YL, Zagordi O, Shilaih M, Nsanwe NN, Mbu ET, Besong LM, Sama BA, Orock E, Kouyos RD, Günthard HF, Metzner KJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1917-1929. doi: 10.1093/jac/dky103.

PMID:
29635462
11.

No Effect of Pegylated Interferon-α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients.

Strouvelle VP, Braun DL, Vongrad V, Scherrer AU, Kok YL, Kouyos RD, Stöckle M, Rauch A, Darling K, Hoffmann M, Metzner KJ, Günthard HF; Zurich Primary HIV Infection Study and the Swiss HIV Cohort Study.

J Infect Dis. 2018 May 25;217(12):1883-1888. doi: 10.1093/infdis/jiy131.

PMID:
29528417
12.

Correction to: Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples.

Lewandowska DW, Zagordi O, Geissberger FD, Kufner V, Schmutz S, Böni J, Metzner KJ, Trkola A, Huber M.

Microbiome. 2017 Oct 12;5(1):137. doi: 10.1186/s40168-017-0351-x. No abstract available.

13.

Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.

Turk T, Bachmann N, Kadelka C, Böni J, Yerly S, Aubert V, Klimkait T, Battegay M, Bernasconi E, Calmy A, Cavassini M, Furrer H, Hoffmann M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni P, Rauch A, Rudin C, Scherrer AU, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

Elife. 2017 Sep 12;6. pii: e28721. doi: 10.7554/eLife.28721.

14.

Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples.

Lewandowska DW, Zagordi O, Geissberger FD, Kufner V, Schmutz S, Böni J, Metzner KJ, Trkola A, Huber M.

Microbiome. 2017 Aug 8;5(1):94. doi: 10.1186/s40168-017-0317-z. Erratum in: Microbiome. 2017 Oct 12;5(1):137.

15.

Unravelling HIV-1 Latency, One Cell at a Time.

Kok YL, Ciuffi A, Metzner KJ.

Trends Microbiol. 2017 Nov;25(11):932-941. doi: 10.1016/j.tim.2017.06.002. Epub 2017 Jun 28. Review.

PMID:
28668335
16.

Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.

Marzel A, Shilaih M, Turk T, Campbell NK, Yang WL, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Calmy A, Battegay M, Cavassini M, Bernasconi E, Schmid P, Metzner KJ, Günthard HF, Kouyos RD; Swiss HIV Cohort Study (SHCS).

HIV Med. 2017 Oct;18(9):667-676. doi: 10.1111/hiv.12507. Epub 2017 Apr 4.

17.

Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.

Beauparlant D, Rusert P, Magnus C, Kadelka C, Weber J, Uhr T, Zagordi O, Oberle C, Duenas-Decamp MJ, Clapham PR, Metzner KJ, Günthard HF, Trkola A.

PLoS Pathog. 2017 Mar 6;13(3):e1006255. doi: 10.1371/journal.ppat.1006255. eCollection 2017 Mar.

18.

Reply to correspondence 'Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a "stochastic" process' by Gonzalez et al., Retrovirology 2017.

Oberle CS, Magnus C, Joos B, Rusert P, Beauparlant D, Kouyos R, Trkola A, Metzner KJ, Günthard HF.

Retrovirology. 2017 Feb 24;14(1):14. doi: 10.1186/s12977-017-0332-y. No abstract available.

19.

In Vivo and in Vitro Proteome Analysis of Human Immunodeficiency Virus (HIV)-1-infected, Human CD4+ T Cells.

Nemeth J, Vongrad V, Metzner KJ, Strouvelle VP, Weber R, Pedrioli P, Aebersold R, Günthard HF, Collins BC.

Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S108-S123. doi: 10.1074/mcp.M116.065235. Epub 2017 Feb 21.

20.

MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.

Huber M, Metzner KJ, Geissberger FD, Shah C, Leemann C, Klimkait T, Böni J, Trkola A, Zagordi O.

J Virol Methods. 2017 Feb;240:7-13. doi: 10.1016/j.jviromet.2016.11.008. Epub 2016 Nov 17.

21.

Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs.

Oberle CS, Joos B, Rusert P, Campbell NK, Beauparlant D, Kuster H, Weber J, Schenkel CD, Scherrer AU, Magnus C, Kouyos R, Rieder P, Niederöst B, Braun DL, Pavlovic J, Böni J, Yerly S, Klimkait T, Aubert V, Trkola A, Metzner KJ, Günthard HF; Swiss HIV Cohort Study (SHCS).

Retrovirology. 2016 Sep 5;13(1):62. doi: 10.1186/s12977-016-0299-0.

22.

Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4(+) T cells.

Kok YL, Vongrad V, Shilaih M, Di Giallonardo F, Kuster H, Kouyos R, Günthard HF, Metzner KJ.

Sci Rep. 2016 Apr 12;6:24157. doi: 10.1038/srep24157.

23.

HIV Whole-Genome Sequencing Now: Answering Still-Open Questions.

Metzner KJ.

J Clin Microbiol. 2016 Apr;54(4):834-5. doi: 10.1128/JCM.03265-15. Epub 2016 Jan 20.

24.

A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing.

St John EP, Simen BB, Turenchalk GS, Braverman MS, Abbate I, Aerssens J, Bouchez O, Gabriel C, Izopet J, Meixenberger K, Di Giallonardo F, Schlapbach R, Paredes R, Sakwa J, Schmitz-Agheguian GG, Thielen A, Victor M, Metzner KJ, Däumer MP; 454 HIV-1 Alpha Study Group.

PLoS One. 2016 Jan 12;11(1):e0146687. doi: 10.1371/journal.pone.0146687. eCollection 2016.

25.

A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations.

Seifert D, Di Giallonardo F, Töpfer A, Singer J, Schmutz S, Günthard HF, Beerenwinkel N, Metzner KJ.

J Mol Biol. 2016 Jan 16;428(1):238-250. doi: 10.1016/j.jmb.2015.12.012. Epub 2015 Dec 19.

26.

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Metzner KJ, Paredes R; CHAIN Minority HIV-1 Variants Working group.

Clin Microbiol Infect. 2016 Feb;22(2):191-200. doi: 10.1016/j.cmi.2015.10.004. Epub 2015 Oct 23.

27.

HIV-1 RNAs are Not Part of the Argonaute 2 Associated RNA Interference Pathway in Macrophages.

Vongrad V, Imig J, Mohammadi P, Kishore S, Jaskiewicz L, Hall J, Günthard HF, Beerenwinkel N, Metzner KJ.

PLoS One. 2015 Jul 30;10(7):e0132127. doi: 10.1371/journal.pone.0132127. eCollection 2015.

28.

A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.

Braun DL, Rauch A, Aouri M, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Müllhaupt B, Metzner KJ, Decosterd L, Böni J, Weber R, Fehr J; Swiss HIV Cohort Study.

PLoS One. 2015 Jul 15;10(7):e0133028. doi: 10.1371/journal.pone.0133028. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0135547.

29.

Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.

Schaerer V, Haubitz S, Kovari H, Ledergerber B, Ambrosioni J, Cavassini M, Stoeckle M, Schmid P, Decosterd L, Aouri M, Böni J, Günthard HF, Furrer H, Metzner KJ, Fehr J, Rauch A; Swiss HIV Cohort Study.

HIV Med. 2015 Nov;16(10):599-607. doi: 10.1111/hiv.12269. Epub 2015 Jul 2.

30.

Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.

Wandeler G, Schlauri M, Jaquier ME, Rohrbach J, Metzner KJ, Fehr J, Ambrosioni J, Cavassini M, Stöckle M, Schmid P, Bernasconi E, Keiser O, Salazar-Vizcaya L, Furrer H, Rauch A; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S.

Open Forum Infect Dis. 2015 Mar 25;2(1):ofv026. doi: 10.1093/ofid/ofv026. eCollection 2015 Jan.

31.

Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .

Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Campbell NK, Taka N, Awasom C, Metzner KJ, van Lunzen J, Feldt T.

J Antimicrob Chemother. 2015 Mar;70(3):922-5. doi: 10.1093/jac/dku470. Epub 2014 Nov 26.

32.

A framework for inferring fitness landscapes of patient-derived viruses using quasispecies theory.

Seifert D, Di Giallonardo F, Metzner KJ, Günthard HF, Beerenwinkel N.

Genetics. 2015 Jan;199(1):191-203. doi: 10.1534/genetics.114.172312. Epub 2014 Nov 17. Erratum in: Genetics. 2015 Apr;199(4):1271.

33.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; CHAIN Minority HIV-1 Variants Working Group.

J Antimicrob Chemother. 2015 Mar;70(3):930-40. doi: 10.1093/jac/dku426. Epub 2014 Oct 21.

34.

[Pathogenesis of HIV-1].

Metzner KJ.

Ther Umsch. 2014 Aug;71(8):443-50. doi: 10.1024/0040-5930/a000536. Review. German.

PMID:
25093308
35.

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.

Metzner KJ, Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Hirsch HH, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

AIDS. 2014 Sep 24;28(15):2231-9. doi: 10.1097/QAD.0000000000000397.

36.

Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations.

Giallonardo FD, Töpfer A, Rey M, Prabhakaran S, Duport Y, Leemann C, Schmutz S, Campbell NK, Joos B, Lecca MR, Patrignani A, Däumer M, Beisel C, Rusert P, Trkola A, Günthard HF, Roth V, Beerenwinkel N, Metzner KJ.

Nucleic Acids Res. 2014 Aug;42(14):e115. doi: 10.1093/nar/gku537. Epub 2014 Jun 27.

37.

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.

Braun DL, Rauch A, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Metzner KJ, Böni J, Weber R, Fehr J.

HIV Med. 2014 Nov;15(10):625-30. doi: 10.1111/hiv.12166. Epub 2014 Jun 4.

38.

An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.

Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, Gabriel C, Izopet J, Kessler HH, Stelzl E, Di Giallonardo F, Schlapbach R, Radonic A, Paredes R, Recordon-Pinson P, Sakwa J, St John EP, Schmitz-Agheguian GG, Metzner KJ, Däumer MP; 454 HIV Alphastudy Group.

J Virol Methods. 2014 Aug;204:31-7. doi: 10.1016/j.jviromet.2014.04.007. Epub 2014 Apr 13.

PMID:
24731928
39.

Breast milk and gut microbiota in African mothers and infants from an area of high HIV prevalence.

González R, Maldonado A, Martín V, Mandomando I, Fumadó V, Metzner KJ, Sacoor C, Fernández L, Macete E, Alonso PL, Rodríguez JM, Menendez C.

PLoS One. 2013 Nov 26;8(11):e80299. doi: 10.1371/journal.pone.0080299. eCollection 2013. Erratum in: PLoS One. 2014;9(3):e92930. Maldonado, Antonio [added]; Martín, Virginia [added]; Metzner, Karin J [added]; Fernández, Leónides [added]; Rodríguez, Juan M [added].

40.

Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-α.

Guennewig B, Roos M, Dogar AM, Gebert LF, Zagalak JA, Vongrad V, Metzner KJ, Hall J.

RNA. 2014 Jan;20(1):61-75. doi: 10.1261/rna.038968.113. Epub 2013 Nov 18.

41.

Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination.

Di Giallonardo F, Zagordi O, Duport Y, Leemann C, Joos B, Künzli-Gontarczyk M, Bruggmann R, Beerenwinkel N, Günthard HF, Metzner KJ.

PLoS One. 2013 Sep 18;8(9):e74249. doi: 10.1371/journal.pone.0074249. eCollection 2013.

42.

Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.

Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Battegay M, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2013 Oct 1;208(7):1102-12. doi: 10.1093/infdis/jit310. Epub 2013 Jul 11.

43.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR.

J Infect Dis. 2013 Mar 15;207(6):893-7. doi: 10.1093/infdis/jis925. Epub 2012 Dec 21.

44.

Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data.

Beerenwinkel N, Günthard HF, Roth V, Metzner KJ.

Front Microbiol. 2012 Sep 11;3:329. doi: 10.3389/fmicb.2012.00329. eCollection 2012.

45.

Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells.

Althaus CF, Vongrad V, Niederöst B, Joos B, Di Giallonardo F, Rieder P, Pavlovic J, Trkola A, Günthard HF, Metzner KJ, Fischer M.

Retrovirology. 2012 Mar 29;9:27. doi: 10.1186/1742-4690-9-27.

46.

Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant.

Bansal V, Metzner KJ, Niederost B, Leemann C, Boni J, Gunthard HF, Fehr JS.

Emerg Infect Dis. 2011 Oct;17(10):1966-8. doi: 10.3201/eid1710.110592. No abstract available.

47.

Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection.

Rieder P, Joos B, Scherrer AU, Kuster H, Braun D, Grube C, Niederöst B, Leemann C, Gianella S, Metzner KJ, Böni J, Weber R, Günthard HF.

Clin Infect Dis. 2011 Dec;53(12):1271-9. doi: 10.1093/cid/cir725. Epub 2011 Oct 12.

48.

Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, Kuster H, Weber R, Guenthard HF.

PLoS One. 2011;6(7):e21734. doi: 10.1371/journal.pone.0021734. Epub 2011 Jul 6.

49.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

50.

A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication.

Huelsmann PM, Hofmann AD, Knoepfel SA, Popp J, Rauch P, Di Giallonardo F, Danke C, Gueckel E, Schambach A, Wolff H, Metzner KJ, Berens C.

BMC Biotechnol. 2011 Jan 11;11:4. doi: 10.1186/1472-6750-11-4.

Supplemental Content

Loading ...
Support Center